Comments
Veego Pharma LLC, promoter of Wintac, has announced the floor price for its proposed delisting offer at ₹220 a share. The delisting proposal of the promoter is subject to approval by the board of directors, shareholders (through postal ballot) and other statutory and regulatory authorities.
Wintac, which focuses on the manufacture of small and large volume parenterals, sterile ophthalmic preparations and also marketing of pharmaceutical specialities catering to niche segments, had reported a loss of ₹0.59 crore for the quarter-ended December 2017 on revenues of ₹10.41 crore.
On Thursday, the shares of Wintac closed at ₹195.40, a gain of 5 per cent on the BSE. Our Bureau
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.